natgillin/translations-raw huggingface dataset:
The first study involved 22 patients aged 12 years and above, who were given Nuwiq for the treatment of bleeding episodes or to prevent bleeding during surgery. 
Prva študija je vključevala 22 bolnikov, starih 12 let in več, ki so prejeli zdravilo Nuwiq za zdravljenje krvavitev ali za preprečevanje krvavitve med kirurškim posegom.
In the five surgeries that occurred during the study, Nuwiq was rated as excellent in preventing bleeding episodes for four surgeries and as moderate to prevent bleeding during one surgical intervention. 
Pri petih kirurških posegih, ki so jih opravili v času študije, je bilo zdravilo Nuwiq pri štirih kirurških posegih ocenjeno kot odlično za preprečevanje krvavitev, pri enem kirurškem posegu pa kot zmerno učinkovito za preprečevanje krvavitev.
The second study involved 32 patients aged 12 years and above who were given Nuwiq to prevent and treat bleeding events as well as to prevent bleeding during surgery. 
Druga študija je vključevala 32 bolnikov, starih 12 let in več, ki so prejeli zdravilo Nuwiq za preprečevanje in zdravljenje krvavitev ter za preprečevanje krvavitve med kirurškim posegom.
How does Nuwiq work? 
Kako zdravilo Nuwiq deluje?
How is Nuwiq used? 
Kako se zdravilo Nuwiq uporablja?
The need for treatment should be reassessed regularly. 
Potrebo po zdravljenju je treba redno ponovno ocenjevati.
However, juvenile rats are more sensitive. 
Vendar pa so mlade podgane bolj občutljive.
This is different to the stresses and strains of everyday life. 
To se razlikuje od stresa in obremenjenosti v vsakdanjem življenju.
In that case, just carry on with the next dose as normal. 
V tem primeru nadaljujte z naslednjim odmerkom kot ponavadi.
The patient should be informed about this at the start of the treatment. 
Bolnik mora biti s tem seznanjen na začetku zdravljenja.
Nine weeks after exposure, this effect was no longer observable. 
9 tednov po izpostavitvi tega učinka ni bilo več možno opaziti.
Do not take more medicine than prescribed. 
Ne jemljite več zdravila, kot je predpisano.
• Inappropriate behaviour 
• neprimerno vedenje
If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. 
Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite, razen če ni že čas za naslednjega.
Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be made. 
Trenutno razpoložljivi podatki so opisani v poglavjih 4.8, 5.1 in 5.2, vendar ni mogoče dati priporočil o odmerjanju.
Interaction studies have only been performed in adults. 
Študije medsebojnega delovanja so bile izvedene le pri odraslih.
• Slow or reduced movement of the body 
• počasno ali okrnjeno gibanje telesa
The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for pregabalin. 
Mehanizem tega tveganja še ni znan in razpoložljivi podatki ne izključujejo možnosti povečanega tveganja pri uporabi pregabalina.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 June 2015 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum pridobitve dovoljenja: 25. junij 2015
Your doctor will determine what dose is appropriate for you. 
Zdravnik bo določil primeren odmerek za vas.
Therefore the effects were considered of little or no clinical relevance. 
Zato se vplivi smatrajo kot malo ali klinično nepomembni.
Pregabalin should be used with caution in these patients. 
Pregabalin je treba pri takšnih bolnikih uporabljati previdno.
Following repeated administration, steady state is achieved within 24 to 48 hours. 
Po večkratni uporabi je stanje dinamičnega ravnovesja doseženo v 24 do 48 urah.
Suicidal ideation and behaviour 
Samomorilno razmišljanje in vedenje
Monotherapy (newly diagnosed patients) 
Monoterapija (na novo diagnosticirani bolniki)
There is no evidence to suggest an associated risk to humans. 
Ni podatkov, ki bi kazali na povezano tveganje za človeka.
After 3 months of treatment, there were no effects on sperm motility. 
Po 3 mesecih zdravljenja, ni bilo vpliva na motiliteto sperme.
In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats. 
Pri mladih podganah se tipi toksičnosti ne razlikujejo kvalitativno od tistih, opaženih pri odraslih podganah.
Swallow the capsule whole with water. 
Kapsulo pogoltnite celo z vodo.
Date of last renewal: DDMMYY 
Datum zadnjega podaljšanja: DDMMLL
Mylan S.A.S 117 Allée des Parcs 69800 Saint-Priest France 
Mylan S.A.S 117 Allée des Parcs 69800 Saint-Priest Francija
Single dose+ 
posamičen odmerek+
• Before taking this medicine you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. 
• Pred uporabo tega zdravila morate svojemu zdravniku povedati, če ste imeli v preteklosti težave z alkoholizmom ali z zlorabo ali odvisnostjo od drog.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 
O neželenih učinkih lahko poročate tudi neposredno na nacionalni center za poročanje, ki je naveden v Prilogi V. Stem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
Interactions and the elderly 
Interakcije pri starejših
The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore, pregabalin should not be used in this age group. 
Varnost in učinkovitost pri otrocih in mladostnikih (mlajših od 18 let) nista ugotovljeni, zato se pregabalina v tej starostni skupini ne sme uporabljati.
• Difficulties with erection 
• težave z erekcijo
If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time. 
Če predložitev PSUR in posodobitev RMP sovpadata, se lahko predložita istočasno.
The marketing authorisation holder (MAH) shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Imetnik dovoljenja za promet (MAH) z zdravilom mora redno posodobljena poročila o varnosti zdravila za to zdravilo predložiti v skladu z zahtevami, določenimi v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in objavljenem na evropskem spletnem portalu o zdravilih.
Pregabalin Mylan Pharma should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). 
Zdravila Pregabalin Mylan Pharma se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno (če koristi za mater jasno prevladajo nad možnim tveganjem za plod).
If you are an older patient (over 65 years of age), you should take Pregabalin Mylan Pharma normally except if you have problems with your kidneys. 
Če ste starejši bolnik (nad 65 let), lahko jemljete zdravilo Pregabalin Mylan Pharma normalno, razen če imate težave z ledvicami.
The clinical relevance of these findings is unknown (see section 5.3). 
Klinični pomen teh ugotovitev ni znan (glejte poglavje 5.3).
TID = Three divided doses 
3-krat/dan = tri deljene odmerke
Tell your doctor if you experience constipation, especially if you are prone to this problem. 
Povejte zdravniku, če se pojavi zaprtost, še posebno, če ste nagnjeni k temu problemu.
INSTRUCTIONS ON USE <For multilayer label only> ‘Peel here' 
NAVODILA ZA UPORABO <Samo za večplastne oznake> ‘Odlepi tukaj'
Pharmacotherapeutic group: Anti-epileptics, other anti-epileptics, ATC code: N03AX16. 
Farmakoterapevtska skupina: antiepileptiki, drugi antiepileptiki, oznaka ATC: N03AX16.
• Take the number of capsules as instructed by your doctor. 
• Vzemite toliko kapsul, kot vam je naročil zdravnik.
The effect of pregabalin on newborns/infants is unknown. 
Učinek pregabalina na novorojenčke/dojenčke ni znan.
• Lorazepam - (used for treating anxiety) 
• lorazepam - (uporablja se za zdravljenje tesnobe)
• Jaundice (yellowing of the skin and eyes). 
• zlatenica (rumeno obarvanje kože in oči)
• Difficulty with or painful urination, incontinence 
• težave z uriniranjem ali boleče uriniranje, inkontinenca
Therefore, you should be careful until you are used to any effect the medicine might have. 
Zato bodite previdni, dokler se ne navadite na vse učinke, ki jih zdravilo lahko ima.
If you experience swollen face or tongue or if your skin turns red and starts to blister or peel you should seek immediate medical advice. 
Če vam zateče obraz ali jezik ali če vaša koža postane rdeča in se na njej pojavijo mehurji ali se začne lupiti, morate nemudoma poiskati zdravniško pomoč.
Pregabalin mean elimination half-life is 6.3 hours. 
Povprečni razpolovni čas izločanja pregabalina je 6,3 ure.
Pregabalin was not teratogenic in mice, rats or rabbits. 
Pregabalin ni bil teratogen pri miših, podganah ali kuncih.
In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the R-enantiomer. 
V predkliničnih raziskavah ni bilo znakov racemizacije S-enantiomera pregabalina v R-enantiomer.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products. 
Našteti neželeni učinki so lahko povezani tudi z osnovno boleznijo in/ali sočasno uporabljenimi zdravili.
• The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day. 
• Odmerek, ki ga je prilagodil vam in vaši bolezni, bo praviloma med 150 mg in 600 mg na dan.
• Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances 
• spremembe zapisa elektrokardiograma (EKG), ki kažejo na motnje srčnega ritma
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
• Increased appetite 
• zvečanje apetita
In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. 
V kliničnem preskušanju za oceno vpliva pregabalina na motiliteto sperme, so bili zdravi moški izpostavljeni pregabalinu v odmerku 600 mg/dan.
• Difficulty with writing properly 
• težave s pisanjem
Pregabalin and lamotrigine were similarly safe and well tolerated. 
Pregabalin in lamotrigin sta si bila podobna glede varnosti in bolniki so ju enako dobro prenašali.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency (very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data)). 
V spodnji preglednici 2 so po organskih sistemih in pogostnosti navedeni vsi neželeni učinki, ki so se pojavili pri več kot enem bolniku in z incidenco, večjo kot pri placebu (zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)).
Women of childbearing potential/Contraception in males and females As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential. 
Ženske v rodni dobi/Kontracepcija pri moških in ženskah Ker možno tveganje za ljudi ni znano, je pri ženskah v rodnem obdobju potrebna uporaba učinkovite kontracepcije.
• Painful menstrual periods 
• boleče menstruacije
In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. 
Pri človeku je navidezni volumen porazdelitve pregabalina po peroralni uporabi približno 0,56 l/kg.
Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections 4.2, 4.8 and 5.1). 
Farmakokinetike pregabalina niso preučevali pri bolnikih, mlajših od 3 mesecev (glejte poglavja 4.2, 4.8 in 5.1).
Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone. 
Kaže, da pregabalin aditivno prispeva k okvari kognitivnega in grobega motoričnega delovanja, ki jo povzroča oksikodon.
Inter-subject pharmacokinetic variability for pregabalin is low (<20%). 
Razlike v farmakokinetiki pregabalina od posameznika do posameznika so majhne (< 20 %).
Pregabalin is not bound to plasma proteins. 
Pregabalin ni vezan na beljakovine v plazmi.
Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge. 
Bolnikom (in skrbnikom bolnikov) je treba svetovati, naj poiščejo zdravniško pomoč, če se pojavijo znaki samomorilnega razmišljanja in vedenja.
A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prekinitvijo zdravljenja s pregabalinom, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
GSP Proizvodi d.o.o. 
SlovenijaGSP Proizvodi d.o.o.
Epilepsy or Generalised Anxiety Disorder: 
Epilepsija ali generalizirana anksiozna motnja:
Mylan Hungary Kft Mylan utca 1, Komárom, 2900, Hungary 
Mylan Hungary Kft Mylan utca 1, Komárom, 2900, Madžarska
Pregabalin Mylan Pharma is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment. 
Zdravilo Pregabalin Mylan Pharma ni namenjeno temu, da bi ga jemali samo, temveč ga je vedno treba uporabljati v kombinaciji z drugimi zdravili proti epilepsiji.
Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age group. 
Parametra Cmax in AUC za pregabalin sta se v vseh starostnih skupinah večala linearno z večanjem odmerka.
If your treatment is stopped it should be done gradually over a minimum of 1 week. 
V tem primeru boste zdravilo opustili postopoma v teku najmanj enega tedna.
Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and 4 to 6 hours in those 7 years of age and older. 
Končni razpolovni čas pregabalina je bil v povprečju približno 3 do 4 ure pri pediatričnih bolnikih, starih do 6 let, ter od 4 do 6 ur pri 7-letnikih in starejših.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25-30% and a delay in tmax to approximately 2.5 hours. 
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25-30 % in tmax se podaljša na približno 2,5 ure.
• Coldness of hands and feet 
• hladne dlani in stopala
Each hard capsule contains either 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg or 300 mg of pregabalin. 
Ena trda kapsula vsebuje 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg ali 300 mg pregabalina.
Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. 
Po odmerku radioaktivno označenega pregabalina je šlo približno 98 % v urinu izločene radioaktivnosti na račun nespremenjenega pregabalina.
Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. 
Zato je treba bolnike med zdravljenjem nadzirati glede znakov samomorilnega razmišljanja in vedenja ter razmisliti o ustreznem zdravljenju.
Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related. 
Kar zadeva prekinitev dolgotrajnega zdravljenja s pregabalinom, podatki kažejo, da sta incidenca in resnost odtegnitvenih simptomov lahko odvisni od odmerka.
• Muscle damage 
• mišične poškodbe
Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. 
Dvoletna študija kancerogenosti s pregabalinom je bila narejena na miših in podganah.
This leaflet was last revised in 
Navodilo je bilo nazadnje revidirano dne: .
The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing ≥30 kg. 
Vrednost AUC je bila pri pediatričnih bolnikih, lažjih od 30 kg, za 30 % nižja zaradi povečanega očistka, prilagojenega telesni masi, ki je bil pri teh bolnikih 43 % v primerjavi z bolniki s telesno maso 30 kg ali več.
Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms. 
Prenehanje uporabe pregabalina lahko povzroči izboljšanje ali izginotje teh simptomov.
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)5- methylhexanoic acid]. 
Učinkovina pregabalin je analog gama-aminomaslene kisline (S)-3-(aminometil)-5-metilheksanojska kislina].
If you have the impression that the effect of Pregabalin Mylan Pharma is too strong or too weak, talk to your doctor or pharmacist. 
Če imate občutek, da je učinek zdravila Pregabalin Mylan Pharma premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly). 
Ob sočasni uporabi pregabalina in opioidov je potrebno razmisliti o ukrepih za preprečevanje zaprtja (predvsem pri ženskah in starejših bolnikih).
In accordance with current clinical practice, if pregabalin has to be discontinued, it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8). 
Če je treba uporabo pregabalina prekiniti, ga je skladno s trenutno klinično prakso, ne glede na indikacijo, priporočljivo zmanjševati postopoma vsaj 1 teden (glejte poglavji 4.4 in 4.8).
If you take more Pregabalin Mylan Pharma than you should Call your doctor or go to the nearest hospital emergency unit immediately. 
Če ste vzeli večji odmerek zdravila Pregabalin Mylan Pharma, kot bi smeli Pokličite zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
200 hard capsules 
200 trdih kapsul
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu/.
You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities. 
Ne vozite, ne upravljajte z zapletenimi stroji in ne sodelujte pri drugih potencialno nevarnih dejavnostih, dokler ne veste, ali to zdravilo poslabša vašo zmožnost za takšne dejavnosti.
No specific pharmacodynamic interaction studies were conducted in elderly volunteers. 
Specifičnih raziskav farmakodinamičnih interakcij pri starejših prostovoljcih ni bilo.
The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below the age of 12 and adolescents has not been established. 
Varnost in učinkovitost pregabalina kot dodatnega zdravljenja epilepsije pri pediatričnih bolnikih, mlajših od 12 let, in pri mladostnikih nista dokazani.
In rare occasions, cases of coma have been reported. 
Redko so poročali o primerih kome.
Multiple dose pharmacokinetics are predictable from single-dose data. 
Farmakokinetiko po več odmerkih je mogoče napovedati iz podatkov za posamičen odmerek.
• Feeling drunk, abnormal style of walking 
• občutek pijanosti, nenormalna hoja
Other medicines and Pregabalin Mylan Pharma Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Pregabalin Mylan Pharma Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
There have also been post-marketing reports of loss of consciousness, confusion and mental impairment. 
V obdobju trženja so poročali tudi o izgubi zavesti, zmedenosti in poslabšanju mentalnih sposobnosti.
Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. 
Oftalmološke preiskave (vključno z določanjem ostrine vida, formalnim določanjem vidnega polja in pregledom očesnega ozadja pri razširjeni zenici) so v nadzorovanih kliničnih preskušanjih opravili pri več kot 3.600 bolnikih.
In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses. 
V običajnih raziskavah farmakološke varnosti pri živalih so le-te pregabalin v klinično pomembnih odmerkih dobro prenašale.
The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. 
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9 % odmerka.
Total pregabalin daily dose * 
tni dnevni odmerek pregabalina*
• Vertigo, problems with balance, fall 
• vrtoglavica, težave z ravnotežjem, padec
• Pregabalin Mylan Pharma may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. 
• Uporaba zdravila Pregabalin Mylan Pharma lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
Pregabalin Mylan Pharma and certain other medicines may influence each other (interaction). 
Zdravilo Pregabalin Mylan Pharma in določena druga zdravila imajo lahko medsebojno delovanje (interakcije).
PHARMACEUTICAL FORM AND CONTENTS Hard capsule. 
FARMACEVTSKA OBLIKA IN VSEBINA trda kapsula
• Blurred vision, double vision 
• zamegljen vid, dvojni vid
• Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines. 
• Nekateri bolniki z diabetesom, ki so se med jemanjem pregabalina zredili, lahko potrebujejo zamenjavo diabetičnih zdravil.
Pregabalin binds to an auxiliary subunit (α2- δ protein) of voltage-gated calcium channels in the central nervous system. 
Pregabalin se veže na pomožno podenoto (beljakovino α2- δ) napetostno odvisnih kalcijevih kanalčkov v osrednjem živčevju.
The safety and efficacy of Pregabalin Mylan Pharma in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. 
Varnost in učinkovitost zdravila Pregabalin Mylan Pharma pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
Very common: may affect more than 1 in 10 people • Dizziness, drowsiness, headache 
Zelo pogosti: pojavijo se lahko pri najmanj 1 od 10 bolnikov • omotica, zaspanost, glavobol
The non-genotoxic mechanism of pregabalin-induced tumour formation in mice involves platelet changes and associated endothelial cell proliferation. 
Negenotoksični mehanizem formacije tumorjev, inducirane s pregabalinom, pri miših vključuje spremembe trombocitov in s tem povezano proliferacijo endotelijskih celic.